You are here

Catalent

FTC request may signal trouble for Novo/Catalent deal

Pharma Voice

Thu, 05/30/24 - 11:09 am

Biopharma M&A activity jumped 71% in Q1 2024

Medical Marketing and Media

Thu, 05/16/24 - 11:37 am

Gilead Sciences

CymaBay Therapeutics

Fusion Pharmaceuticals

FTC seeks more information on Novo Nordisk parent-Catalent deal

Reuters

Fri, 05/3/24 - 11:28 am

FTC Will Have More Time to Review Novo’s $16.5B Catalent Buy

BioSpace

Fri, 04/5/24 - 11:52 am

Novo Nordisk and Catalent deal: net positive or negative for industry?

Biopharma Reporter

Tue, 02/20/24 - 11:06 am

3 questions hanging over the Novo-Catalent deal

Pharma Voice

Wed, 02/14/24 - 10:55 am

drug manufacturing

As Catalent prepares to join Novo family, CDMO's sales continue to slide

Fierce Pharma

Fri, 02/9/24 - 11:21 am

FDA finds control lapses at Catalent plant being sold to Novo

Reuters

Tue, 02/6/24 - 11:36 pm

drug manufacturing

Novo Holdings acquires Catalent in $16.5B deal, aiming to boost Wegovy production as demand soars

Medical Marketing and Media

Mon, 02/5/24 - 11:06 pm

drug manufacturing

Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply

CNBC

Mon, 02/5/24 - 10:10 am

drug manufacturing

Catalent delays quarterly filing with SEC on $700 mln impairment charge

Reuters

Tue, 11/14/23 - 11:18 am

Shares of Wegovy Partner Catalent Jump After Striking Deal With Activist Investor Elliott

Investopedia

Wed, 08/30/23 - 10:03 am

Elliott Management

Catalent facing board shake-up pressure from activist investor Elliott

Fierce Pharma

Fri, 07/21/23 - 10:06 am

activist investors

Catalent Delays Earnings Call, Shaves $400M Off FY23 Guidance

BioSpace

Tue, 05/9/23 - 10:37 am

Danaher backs away from Catalent as CDMO struggles with productivity problems: report

Fierce Pharma

Tue, 04/18/23 - 10:15 am

Catalent Hits Four-Month High As Danaher Reportedly Mulls A Takeover

Investors Business Daily

Tue, 02/7/23 - 11:14 am

Thermo Fisher Scientific

Sarepta marches forward with its potential DMD gene therapy and an expanded Catalent manufacturing deal

Endpoints

Thu, 01/5/23 - 04:58 pm

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Catalent to build a new $40M analytical services facility in North Carolina's Research Triangle

Endpoints

Wed, 12/14/22 - 07:25 pm

analytical services

Exelixis Inks Third Collaboration Deal in a Week, This Time with Catalent

BioSpace

Thu, 11/3/22 - 07:34 pm

antibody-drug conjugate

Catalent buys partially built biologics plant with plans to shell out $160M to finish it

Fierce Pharma

Thu, 04/7/22 - 10:32 am

drug manufacturing

Pages